Eli Lilly’s Zepbound for Weight Loss Shows Promise in Sleep Apnea Treatment
Sleep Apnea is a common disorder with severe potential health implications. Its link with obesity is well-documented and the search for effective treatments is continuous. One promising candidate is Zepbound, a weight loss drug developed by Eli Lilly.
Sleep apnea is a severe sleep disorder that occurs when a person's breathing repeatedly stops and starts during sleep. There are two main types: obstructive sleep apnea, the more prevalent form, and central sleep apnea. It's a potentially severe disorder with symptoms like gasping for air during sleep, snoring loudly, and waking up feeling tired.
Obesity is a significant risk factor for sleep apnea. About 70% of people with obstructive sleep apnea are overweight or obese. The excess fat deposits around the upper airway obstruct breathin...